Moderna Raises 2026 Revenue Growth Outlook to 15%–25%

Moderna now expects revenue to grow 15% to 25% in 2026, up from its previous forecast of up to 10%. The company cited traction for newer vaccines and stabilizing demand for its COVID-19 vaccine.